Irritable Bowel Syndrome (IBS) Treatment Market Scope and Analysis Report by 2028
Irritable Bowel Syndrome (IBS) Treatment Market Report Scope
Report Attribute | Details |
---|---|
Market size in 2020 | US$ 2.15 Billion |
Market Size by 2028 | US$ 4.6 Billion |
Global CAGR (2020 - 2028) | 10.1% |
Historical Data | 2018-2019 |
Forecast period | 2021-2028 |
Segments Covered |
By Type
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
Irritable Bowel Syndrome (IBS) Treatment Market – by Type
- IBS with Diarrhea (IBS-D)
- IBS with Constipation (IBS-C)
- Mixed IBS (IBS-M)
Irritable Bowel Syndrome (IBS) Treatment Market – by Product
- Rifaximin
- Eluxadoline
- Linaclotide
- Lubiprostone
- Others
Irritable Bowel Syndrome (IBS) Treatment Market – by Distribution Channel
- Hospitals Pharmacies
- Drug Stores and Retail Pharmacies
- Online Pharmacies
Irritable Bowel Syndrome (IBS) Treatment Market– by Geography
North America
- US
- Canada
- Mexico
Europe
- France
- Germany
- Italy
- UK
- Spain
- Rest of Europe
Asia Pacific (APAC)
- China
- India
- South Korea
- Japan
- Australia
- Rest of APAC
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Rest of MEA
South and Central America (SCAM)
- Brazil
- Argentina
- Rest of SCAM
Company Profiles
- Ironwood Pharmaceuticals, Inc.
- AbbVie.
- Sebela Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Alfasigma S.p.A.
- Astellas Pharma Inc.
- AstraZeneca
- Synthetic Biologics, Inc.
- Bausch + Lomb Incorporated
- Lannett Company Inc